15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Organon & Co, 0 rate it Buy or better, 3 sit at Hold, and 2 rate it Sell or worse, a moderate sell consensus. Targets span $8.00 to $14.00, a moderate spread. The average target of $11.40 sits 16% below the current $13.53. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.05 next quarter toward $3.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Sell
Strong Buy00%
Buy00%
Hold360%
Sell240%
Strong Sell00%
Based on 5 analysts giving stock ratings to Organon & Co.
As of Jul, 0 of 5 firms rate OGN a Buy (3 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
OGN EPS & revenue forecast
EPS · NEXT QUARTER
$1.05
Range $1.05 – $1.05 · 1 analysts · +4% YoY
Next period, 1 analysts expect Organon & Co to earn $1.05 a share (range $1.05 – $1.05), versus $1.01 a year earlier. Full-year consensus is $3.62, growing to $3.64 the year after.
REVENUE · NEXT QUARTER
$1.6B
Range $1.5B – $1.6B · 1 analysts · -2% YoY
Revenue is expected to reach $1.6B (range $1.5B – $1.6B), -2.1% year-over-year. Full-year consensus is $6.1B, rising to $6.2B next year.
Top analysts covering Organon & Co
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OGN.
#1
David Amsellem
Piper Sandler · Rank #95
Hold
$14.00+3.5% to target
Overall win rate
50%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #136
Sell
No targeton OGN
Overall win rate
46%
+ Follow
#3
Balaji Prasad
Barclays · Rank #147
Buy
$24.00+77.4% to target
Overall win rate
44%
+ Follow
#4
Terence Flynn
Morgan Stanley
Hold
$9.00-33.5% to target
Coverage
—
+ Follow
#5
GS
Glen Santangelo
Barclays
Sell
$8.00-40.9% to target
Coverage
—
+ Follow
OGN stock forecast FAQ
What is OGN's average 12-month price target?+
The 5 analysts with a live target average $11.40 for Organon & Co over the next 12 months, ranging from a $14.00 high to a $8.00 low.
Is OGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Sell. Of the 5 analyst ratings, 0 are Buy or Strong Buy, 3 are Hold, and 2 are Sell or Strong Sell.
What are the highest and lowest price targets for OGN?+
The Street-high target is $14.00 (BNP Paribas), and the Street-low is $8.00 (Barclays). The average of all 5 active targets is $11.40.
How many Wall Street analysts cover OGN?+
5 analysts have an active rating on Organon & Co, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering OGN?+
Among analysts who currently cover OGN, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #95). Their current call is Hold with a $14.00 target.
What is Organon & Co's projected EPS for next quarter?+
The consensus estimate is $1.05 per share (range $1.05 – $1.05) across 1 analysts. Full-year EPS is projected at $3.62, rising to $3.64 the following year.
How much revenue is Organon & Co expected to report next quarter?+
Consensus revenue is $1.6B (range $1.5B – $1.6B). Full-year revenue is projected at $6.1B, growing to $6.2B next year.
Have analysts been upgrading or downgrading OGN lately?+
As of Jul, 0 of 5 firms rate OGN a Buy (3 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
